Functional and structural consequences of fibrinogen γ-chain variants associated with thrombotic phenotype in

Tomas Simurda1, Eliska Ceznerova2, Zuzana Kolkova3

  • 1National Centre of Hemostasis and Thrombosis, Department of Hematology and Transfusiology, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin and University Hospital Martin, Martin, Slovakia.

Thrombosis Research
|April 2, 2026
PubMed

Fibrinogen is a key determinant of clot formation and stability in the final phase of coagulation. Genetic variants in the fibrinogen γ-chain gene (FGG) are a frequent cause of congenital fibrinogen disorders (CFDs) and are associated with marked heterogeneity of clinical presentation, including thrombosis. Increasing evidence indicates that genetic findings alone are insufficient to predict thrombotic risk. We performed a comprehensive molecular, functional, and ultrastructural characterization of 20 patients from Czechia and Slovakia carrying FGG variants. Genetic analysis was combined with fibrin polymerization and fibrinolysis assays, fibrinopeptide release measurements, and scanning electron microscopy of fibrin clots. Five previously unreported pathogenic fibrinogen variants γp.T60A, γp.Y237H, γp.Y306C, γp.G310E, and γp.H333Y were identified. Although 60% of patients were clinically asymptomatic, 30% developed thrombotic manifestations in the absence of established thrombotic risk factors. Functional studies demonstrated delayed fibrin polymerization, reduced clot optical density, and prolonged fibrinolysis despite residual fibrin formation. Ultrastructural analysis revealed markedly altered fibrin clot architecture, characterized by abnormal fiber diameters and increased fiber density compared with controls, consistent with a dense, poorly lysable fibrin network. These findings indicate that FGG variants may promote thrombosis through qualitative alterations of fibrin structure and impaired fibrinolysis rather than fibrinogen deficiency alone. Integration of genetic, functional, and structural analyses is therefore essential for accurate assessment of thrombotic risk in patients with CFDs.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
Fibril-associated Collagen01:11

Fibril-associated Collagen

Fibril-associated collagens are a type of collagens present in the extracellular matrix with interrupted triple helices or FACIT (Fibril-associated collagens interrupted triple-helices). FACIT help connect and attach the collagen fibrils with each other as well as with other proteins of the extracellular matrix.
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
3.6K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
10.2K
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
13.0K
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.8K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
112